Expertise in
20
conditions

Dr. Olivier Rixe

Hematology | Oncology
New Mexico Cancer Care Associates
490A W Zia Rd, 
Santa Fe, NM 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
20
conditions
New Mexico Cancer Care Associates
490A W Zia Rd, 
Santa Fe, NM 

Overview

Olivier Rixe is a Hematologist and an Oncologist practicing medicine in Santa Fe, New Mexico.

Dr. Rixe is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Melanoma, Glioblastoma, Astrocytoma, and Glioma.

He is actively involved in clinical research, co-authoring 31 peer reviewed articles and participating in 17 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in OH

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

New Mexico Cancer Care Associates
490A W Zia Rd, Santa Fe, NM 87505
Other Locations
University of New Mexico Medical Group Inc
933 Bradbury Dr SE Ste 2222, Albuquerque, NM 87106

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: April 07, 2026
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors
A Phase I, Open-label, Dose Finding Study to Assess the Safety, Tolerability, PK, and Preliminary Efficacy of OBT076, a CD205-directed ADC, in Recurrent and/or Metastatic CD205+ Solid Tumors
Enrollment Status: Recruiting
Publish Date: September 16, 2025
Intervention Type: Drug
Study Drug: OBT076
Study Phase: Phase 1
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2026
Intervention Type: Diagnostic test
Study Phase: Not Applicable
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Radiation
Study Drugs: Concomitant Temozolomide (TMZ), Procarbazine, Adjuvant Temozolomide (TMZ), CCNU, Vincristine
Study Phase: Phase 3
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Drug
Study Drug: Tumor Lysate, Particle-Loaded, Dendritic Cell Vaccine
Study Phase: Phase 2
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: May 01, 2023
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 1
View 8 Less Clinical Trials

31 Total Publications

Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan.
Correlation between tumor growth rate and survival in patients with metastatic breast cancer treated with trastuzumab deruxtecan.
Journal: The oncologist
Published: December 22, 2024
Similar Doctors
Expertise in
24
conditions
Dr. Leslie Andritsos
Hematology
Expertise in
24
conditions
Dr. Leslie Andritsos
Hematology

Cancer Center Pharmacy

Albuquerque, NM 
 (1.1 miles away)
505-272-4946
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leslie Andritsos is a Hematologist practicing medicine in Albuquerque, New Mexico. Dr. Andritsos is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Hairy Cell Leukemia (HCL), Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Bone Marrow Transplant, and Splenectomy.

Expertise in
15
conditions
Dr. Ursa Brown
Oncology
Expertise in
15
conditions
Dr. Ursa Brown
Oncology

Christus St Vincent Medical Oncologists

490 W Zia Rd Ste 210, 
Santa Fe, NM 
 (56.9 miles away)
505-913-8900
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ursa Brown is an Oncologist practicing medicine in Santa Fe, New Mexico. Dr. Brown is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Pancreatic Cancer, Familial Pancreatic Cancer, and Cholangiocarcinoma (Bile Duct Cancer). Dr. Brown is board certified in American Board Of Internal Medicine. Dr. Brown is currently accepting new patients.

Expertise in
21
conditions
Dr. Karen Finkelstein
Oncology
Expertise in
21
conditions
Dr. Karen Finkelstein
Oncology

Office

2025 Galisteo St Ste B, 
Santa Fe, NM 
 (56.9 miles away)
505-843-7813
Languages Spoken:
English
See accepted insurances

Karen Finkelstein is an Oncologist practicing medicine in Santa Fe, New Mexico. Dr. Finkelstein is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Malignant Mixed Mullerian Tumor, Sertoli-Leydig Cell Tumor, Oophorectomy, and Hernia Surgery.

Frequently Asked Questions about Dr. Olivier Rixe

How do I make an appointment with Dr. Olivier Rixe?

You can book an appointment with Dr. Olivier Rixe by calling their office at 505-913-8900. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Olivier Rixe a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Olivier Rixe is classified as an Distinguished expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Olivier Rixe specialize in?

While Dr. Olivier Rixe is a Hematology, they have specific expertise in Melanoma, Glioblastoma, and Astrocytoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Olivier Rixe participate in research or clinical trials?

Yes. Dr. Olivier Rixe has published 31 articles and abstracts on conditions like Melanoma. You can view a list of Dr. Olivier Rixe's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Olivier Rixe accept my insurance?

Dr. Olivier Rixe accepts most major insurance plans, including Blue Cross Blue Shield and Humana. We recommend calling the office directly at 505-913-8900 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rixe's expertise for a condition
ConditionClose
    View All 17 Advanced Conditions
    View All 69 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile